skip to main content
Idioma:

Cost‐of‐illness of psoriasis – results of a German cross‐sectional study

Jungen, D. ; Augustin, M. ; Langenbruch, A. ; Zander, N. ; Reich, K. ; Strömer, K. ; Thaci, D. ; Purwins, S. ; Radtke, M. ; Gutknecht, M.

Journal of the European Academy of Dermatology and Venereology, 2018-01, Vol.32 (1), p.174-180 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
  • Título:
    Cost‐of‐illness of psoriasis – results of a German cross‐sectional study
  • Autor: Jungen, D. ; Augustin, M. ; Langenbruch, A. ; Zander, N. ; Reich, K. ; Strömer, K. ; Thaci, D. ; Purwins, S. ; Radtke, M. ; Gutknecht, M.
  • É parte de: Journal of the European Academy of Dermatology and Venereology, 2018-01, Vol.32 (1), p.174-180
  • Notas: Conflicts of interest
    The study was supported by Biogen, Ismaning, Germany.
    Funding sources
    M. Augustin has been working as an advisor and/or presenter and/or participant at clinical studies for the following companies: Abbott/AbbVie, Almirall‐Hermal, Amgen, Biogen Idec, Celgene, Centocor, Eli Lilly, Janssen‐Cilag, Leo Pharma, medac, MSD (previously Essex, Schering‐Plough), Novartis, Pfizer (previously Wyeth). M. Radtke has been working as an advisor and/or presenter and/or participant at clinical studies for the following companies: Abbott/AbbVie, Almirall‐Hermal, Amgen, Beiersdorf, Biogen Idec, Celgene, Centocor, Eli Lilly, Galderma, Janssen‐Cilag, Leo Pharma, medac, MSD (previously Essex, Schering‐Plough), Novartis, Pfizer (previously Wyeth). K. Reich has been an advisor and/or received speaker's honoraria and/or received grants and/or participated in clinical trials of the following companies: Abbvie, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Covagen, Forward Pharma, GlaxoSmithKline, Janssen‐Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme Corp., Novartis, Pfizer, Regeneron, Takeda, UCB Pharma, Xenoport. A. Langenbruch, M. Gutknecht, D. Jungen, S. Purwins, K. Strömer, D. Thaci and N. Zander do not have any conflicts of interest to declare.
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Background Though psoriasis poses a substantial chronic socio‐economic burden, few studies have addressed the economic impact in Germany. Objectives The objective was to evaluate the annual costs of psoriasis in Germany from the societal perspective. Methods A cross‐sectional study was performed in randomly selected German dermatology practices and clinics in 2013/2014 using standardized questionnaires of illness‐related costs. Costs were grouped by perspective and category as well as analysed by sex and age. Group differences were tested by non‐parametric tests. Results Complete data were obtained from 1158 patients in 132 centres. Annual average costs for patients with psoriasis: total costs € 5543 ± € 8044, systemic treatment costs (paid by the statutory health insurances [SHI]) € 3733 ± € 7322, out‐of‐pocket costs € 224 ± € 406, total SHI costs € 4940 ± € 7533, direct costs € 5164 ± € 7581 and indirect costs € 379 ± € 2087. Significant higher costs in male and significant lower costs in 65+‐year‐old patients were found. Conclusions Psoriasis induces a considerable economic burden. Between 2003 and 2014, costs have markedly shifted from hospital, out‐of‐pocket and indirect costs towards systemic drug costs.
  • Editor: England
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.